TREA

88424911 - DRIVEN BY SCIENCE INSPIRED BY HOPE

Follow

Information

  • Trademark
  • 88424911
  • Serial Number
    88424911
  • Filing Date
    May 10, 2019
    5 years ago
  • Transaction Date
    December 02, 2019
    4 years ago
  • Status Date
    December 02, 2019
    4 years ago
  • Published for Opposition Date
    October 08, 2019
    4 years ago
  • Location Date
    December 02, 2019
    4 years ago
  • Status Code
    605
  • Current Location
    GENERIC WEB UPDATE
    Employee Name
    BUTLER, MIDGE FAE
  • Attorney Docket Number
    029492.031
    Attorney Name
    Devon E. White
    Law Office Assigned Location Code
    L70
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
DRIVEN BY SCIENCE INSPIRED BY HOPE
Case File Statements
  • GS0051: Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders
Case File Event Statements
  • 12/2/2019 - 4 years ago
    18 - ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION Type: MAB5
  • 12/2/2019 - 4 years ago
    17 - ABANDONMENT - AFTER PUBLICATION Type: ABN5
  • 11/26/2019 - 4 years ago
    16 - TEAS EXPRESS ABANDONMENT RECEIVED Type: EXAR
  • 10/28/2019 - 4 years ago
    15 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF
  • 10/8/2019 - 4 years ago
    14 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 10/8/2019 - 4 years ago
    13 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 9/18/2019 - 4 years ago
    12 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 9/5/2019 - 5 years ago
    11 - ASSIGNED TO LIE Type: ALIE
  • 9/2/2019 - 5 years ago
    10 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 8/30/2019 - 5 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/30/2019 - 5 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/30/2019 - 5 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/1/2019 - 5 years ago
    6 - NOTIFICATION OF PRIORITY ACTION E-MAILED Type: GPRN
  • 8/1/2019 - 5 years ago
    5 - PRIORITY ACTION E-MAILED Type: GPRA
  • 8/1/2019 - 5 years ago
    4 - PRIORITY ACTION WRITTEN Type: CPRA
  • 7/25/2019 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/25/2019 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 5/14/2019 - 5 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP